Development of bio-marine skin products.

   EGM  October 16th 2020

  New Board August 20th 2020

New office, Oslo.  August 1st 2020

AGM 2020.  June 24th 2020 

   Update BlueBio.  June 9th 2020 

   Loan from IN   March 23rd 2020

   17.3 mill NOK from BlueBio Cofund.  Jan 1st 2020

 Update shareholders (aksjebok).  September 12th 2019

Regenics AS is a private Norwegian biotechnology company based in Oslo. The business concept is to develop and patent marine technologies and products from salmon roe for therapeutic and cosmetic applications.

Wound Healing - Skin diseases

Regenics is developing several products for therapeutic skin applications. The most advanced is VERNEX® for  wound healing. Line extension development involve devices for topical psoriasis and atopic dermatitis. The technology may have the capacity to support living cells in future artificial 3D-skin skin (COLLEX®.)

Vernex® - medical device for wound healing

VERNEX® is a medical device under development using an active marine ingredient extracted from salmon roe without using organic solvents, additions or preservatives and are therefore purely natural products. Regenics’ idea is to locally revive the regenerative abilities of skin cells for therapeutic purposes.

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.